Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT7480 in Nectin-4 positive advanced solid tumors
NCT05163041Phase 2Active, not recruiting
- Sponsor
- Bicycle Therapeutics
- Start
- Nov 2021
- Primary completion
- Aug 2026
- Modality
- Prophylactic Vaccines, Cyclic Peptides, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
A Phase 2 trial of BT7480 in urothelial carcinoma (UC), head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), ovarian carcinoma, breast carcinoma, sponsored by Bicycle Therapeutics. Started Nov 2021; status: active, not recruiting.
02
Drugs
BT7480
03
Conditions
urothelial carcinoma (UC)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)ovarian carcinomabreast carcinoma
Beyond the preview
Go deeper on NCT05163041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05163041.